P. Makras

发表

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.

A. Grossman, G. Kaltsas, D. Papadogias, 2005, Endocrine-related cancer.

Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis

K. Toulis, S. Polyzos, P. Makras, 2011, Hormones.

Papillary thyroid microcarcinoma presenting as lymph node metastasis — a diagnostic challenge: case report and systematic review of literature

M. Alevizaki, S. Polyzos, P. Makras, 2012, Hormones.

Epidemiology and Economic Burden of Osteoporosis in Greece

C. Cooper, J. Kanis, E. McCloskey, 2013 .

Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis

S. Papapoulos, P. Makras, 2008, Nature Clinical Practice Endocrinology &Metabolism.

Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations.

S. Polyzos, M. Yavropoulou, P. Makras, 2021, Maturitas.

Novel therapies for osteoporosis.

P. Makras, A. Anastasilakis, S. Delaroudis, 2015, Metabolism: clinical and experimental.

THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.

S. Polyzos, P. Makras, A. Anastasilakis, 2018, European journal of endocrinology.

Serum 25-hydroxyvitamin D status, quantitative ultrasound parameters, and their determinants in Greek population

G. Dedoussis, P. Makras, I. Dontas, 2018, Archives of Osteoporosis.

Bazedoxifene for the treatment of osteoporosis

M. Yavropoulou, P. Makras, A. Anastasilakis, 2019, Expert opinion on pharmacotherapy.

Advances in the detection and management of neuroendocrine (carcinoid and pancreatic islet cell) tumours

A. Grossman, G. Kaltsas, D. Papadogias, 2006 .

Carcinoid syndrome and carcinoid crisis secondary to a metastatic carcinoid tumour of the lung: a therapeutic challenge.

G. Kaltsas, D. Papadogias, P. Makras, 2007, European journal of gastroenterology & hepatology.

Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments

P. Makras, A. Anastasilakis, A. Dede, 2017, Expert opinion on investigational drugs.

Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.

S. Polyzos, P. Makras, A. Anastasilakis, 2013, The Journal of clinical endocrinology and metabolism.

Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment

S. Polyzos, E. Terpos, P. Makras, 2015, Expert opinion on therapeutic targets.

To screen or not to screen for osteoporosis amongst post-menopausal women with one prior osteoporotic fracture in Greece

K. Souliotis, P. Makras, C. Golna, 2022, Aging Clinical and Experimental Research.

Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment

T. Rachner, L. Hofbauer, S. Polyzos, 2019, Osteologie.

Clinical Features of 24 Patients With Rebound‐Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

S. Polyzos, P. Makras, A. Anastasilakis, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Skeletal Diseases in Cushing’s Syndrome: Osteoporosis versus Arthropathy

G. Kaltsas, P. Makras, 2010, Neuroendocrinology.

The 2018 Guidelines for the diagnosis and treatment of osteoporosis in Greece

E. Chronopoulos, P. Makras, A. Anastasilakis, 2019, Archives of Osteoporosis.

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review

M. Yavropoulou, A. Palermo, G. Tabacco, 2021, Journal of clinical medicine.

Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation

A. Iliopoulos, P. Makras, A. Anastasilakis, 2020, Bone reports.

Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece

P. Sfikakis, M. Yavropoulou, A. Tsolakidis, 2022, Archives of Osteoporosis.

Combination and sequential treatment in women with postmenopausal osteoporosis

S. Polyzos, M. Yavropoulou, P. Makras, 2020, Expert opinion on pharmacotherapy.

Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series

G. Kaltsas, R. Egeler, A. Carret, 2016, Mediterranean journal of hematology and infectious diseases.

Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities.

A. Grossman, A. Pittas, A. Protogerou, 2007, QJM : monthly journal of the Association of Physicians.

The diagnosis and differential diagnosis of endogenous Cushing's syndrome.

G. Kaltsas, D. Papadogias, P. Makras, 2006, Hormones.

Extra-skeletal effects of bisphosphonates.

A. Papavassiliou, M. Yavropoulou, P. Makras, 2020 .

The role of cytokines and adipocytokines in zoledronate‐induced acute phase reaction in postmenopausal women with low bone mass

S. Polyzos, P. Makras, A. Anastasilakis, 2012, Clinical endocrinology.

Effect of 4 weeks of basic military training on peripheral blood leucocytes and urinary excretion of catecholamines and cortisol

D. Pappas, G. Papatheodorou, G. Bourikas, 2005, Journal of sports sciences.

Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment

M. Doulberis, J. Kountouras, S. Polyzos, 2018, Hormones.

Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease

J. Kountouras, S. Polyzos, E. Terpos, 2016, Journal of Bone and Mineral Metabolism.

Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?

C. Mantzoros, S. Polyzos, E. Douni, 2019, Metabolism: clinical and experimental.

Irisin in metabolic diseases

C. Mantzoros, J. Kountouras, S. Polyzos, 2018, Endocrine.

Performance of the Mini Nutritional Assessment Score in the Detection of Vitamin D Status in an Elderly Greek Population

K. Toulis, G. Lyritis, P. Makras, 2012, Hormone and Metabolic Research.

Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society.

E. McCloskey, M. Zillikens, S. Polyzos, 2019, Bone.

2011 guidelines for the diagnosis and treatment of osteoporosis in Greece.

G. Lyritis, G. Vaiopoulos, P. Makras, 2012, Journal of musculoskeletal & neuronal interactions.

Management of parathyroid disorders: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society

M. Yavropoulou, P. Makras, A. Anastasilakis, 2020, Hormones.

Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview

S. Polyzos, P. Makras, A. Anastasilakis, 2018, Hormones.

Bone disease in primary hyperparathyroidism.

P. Makras, A. Anastasilakis, 2017, Metabolism: clinical and experimental.

Gender Predilection in Sporadic Parathyroid Adenomas

M. Yavropoulou, P. Makras, A. Anastasilakis, 2020, International journal of molecular sciences.

Questions and facts regarding denosumab discontinuation among postmenopausal women

P. Makras, A. Anastasilakis, 2020, Expert opinion on drug safety.

Bone metabolism in Langerhans cell histiocytosis

G. Kaltsas, P. Makras, A. Anastasilakis, 2018, Endocrine connections.

Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans’ cell histiocytosis

G. Kaltsas, P. Makras, A. Anastasilakis, 2012, Pituitary.

Systemic and endocrine manifestations of Langerhans’ cell histiocytosis: current concepts in diagnosis and management

G. Kaltsas, P. Makras, G. Piaditis, 2007, Expert review of endocrinology & metabolism.

Endocrine manifestations in Langerhans cell histiocytosis

G. Chrousos, A. Grossman, G. Kaltsas, 2007, Trends in Endocrinology & Metabolism.

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults

Jason R. Young, M. Hermiston, E. Diamond, 2022, Blood.

Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene.

S. Kant, S. Papapoulos, P. Makras, 2008, The Journal of clinical endocrinology and metabolism.

Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis

S. Polyzos, P. Makras, A. Anastasilakis, 2013, Clinical endocrinology.

The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation.

S. Polyzos, M. Yavropoulou, S. Papapoulos, 2021, The Journal of clinical endocrinology and metabolism.

High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas

G. Kaltsas, D. Papadogias, P. Makras, 2009, Clinical endocrinology.

Adult Langerhans Cell Histiocytosis and the Skeleton

P. Makras, A. Anastasilakis, Danae Georgakopoulou, 2022, Journal of clinical medicine.

Periostin and sclerostin levels in juvenile Paget's disease.

G. Mintziori, S. Polyzos, E. Terpos, 2017, CLINICAL CASES IN MINERAL AND BONE METABOLISM.

GH deficiency in adults.

G. Kaltsas, D. Papadogias, P. Makras, 2003, Hormones.

The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.

S. Polyzos, S. Papapoulos, P. Makras, 2020, Bone.

Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.

S. Polyzos, P. Makras, A. Anastasilakis, 2015, Metabolism: clinical and experimental.

Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?

S. Polyzos, M. Yavropoulou, P. Makras, 2018, Calcified Tissue International.

A case report of subacute thyroiditis during pregnancy: difficulties in differential diagnosis and changes in cytokine levels

P. Makras, A. Anastasilakis, S. Gerou, 2011, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass

S. Polyzos, E. Terpos, M. Yavropoulou, 2019, Journal of musculoskeletal & neuronal interactions.

Low bone mineral density and high bone turnover in patients with non-Hodgkin's lymphoma (NHL) who receive frontline therapy: Results of a multicenter prospective study

M. Dimopoulos, M. Angelopoulou, G. Pangalis, 2011 .

The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis.

S. Polyzos, M. Yavropoulou, P. Makras, 2022, Bone.

Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.

S. Polyzos, S. Papapoulos, P. Makras, 2012, Bone.

Off-label uses of denosumab in metabolic bone diseases.

S. Polyzos, P. Makras, A. Anastasilakis, 2019, Bone.

Skeletal implications of isolated bone marrow mastocytosis

P. Makras, 2011, Haematologica.

A 41-year-old man with a vertebral fracture and bone marrow mastocytosis.

P. Makras, P. Kokkoris, 2010, Journal of musculoskeletal & neuronal interactions.

Approach to the management of β thalassemia major associated osteoporosis - a long-standing relationship revisited

M. Yavropoulou, A. Kattamis, P. Makras, 2022, Acta bio-medica : Atenei Parmensis.

Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece

K. Souliotis, P. Makras, C. Golna, 2023, Patient preference and adherence.

Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net

G. Kaltsas, E. Passoni, M. Aricò, 2013, Orphanet Journal of Rare Diseases.

Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures.

D. Tsalikakis, M. Yavropoulou, J. Yovos, 2017, European journal of endocrinology.

Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature.

S. Polyzos, P. Fotiadis, D. Molyva, 2013, Metabolism: clinical and experimental.

Cladribine therapy in adults with advanced Langerhans cell histiocytosis

G. Kaltsas, M. Voulgarelis, P. Makras, 2013, Leukemia & lymphoma.

Langerhans' cell histiocytosis in an adult patient manifested as recurrent skull lesions and Diabetes Insipidus.

G. Kaltsas, D. Papadogias, P. Makras, 2004, Hormones.

Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH)

E. Andreakos, D. Papadogias, P. Makras, 2005, Neuroradiology.

Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosis.

K. Revelos, G. Kaltsas, E. Andreakos, 2015, The Journal of clinical endocrinology and metabolism.

Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis.

G. Kaltsas, S. Polyzos, E. Terpos, 2012, The Journal of clinical endocrinology and metabolism.

Spontaneous Gonadotrophin Deficiency Recovery in an Adult Patient with Langerhans Cell Histiocytosis (LCH)

G. Kaltsas, D. Papadogias, P. Makras, 2005, Pituitary.

Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity.

G. Kaltsas, S. Polyzos, E. Terpos, 2017, Metabolism: clinical and experimental.

Prevalence of the BRAF V600E mutation in Greek adults with Langerhans cell histiocytosis

E. Andreakos, M. Yavropoulou, C. Allen, 2022, Pediatric hematology and oncology.

Reduced bone mineral density in adult patients with Langerhans cell histiocytosis

G. Kaltsas, E. Terpos, P. Makras, 2012, Pediatric blood & cancer.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas

O. Tsave, M. Yavropoulou, J. Yovos, 2020, JBMR plus.

Medical treatment of hypercalcaemia

S. Papapoulos, P. Makras, 2009, Hormones.

Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesis.

K. Toulis, S. Polyzos, P. Makras, 2011, Medical hypotheses.

Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder

A. Tzallas, D. Tsalikakis, T. Eleftheriadis, 2020, Biomedicines.

Serum profile of microRNAs linked to bone metabolism during sequential treatment for postmenopausal osteoporosis.

L. Hofbauer, M. Yavropoulou, M. Rauner, 2020, The Journal of clinical endocrinology and metabolism.

Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis

O. Tsave, M. Yavropoulou, J. Yovos, 2018, The Journal of clinical endocrinology and metabolism.

Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece

P. Sfikakis, M. Yavropoulou, A. Tsolakidis, 2022, Archives of Osteoporosis.

Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.

M. Yavropoulou, F. Papadopoulou, S. Papapoulos, 2017, European journal of endocrinology.

Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study

M. Dimopoulos, E. Kastritis, M. Gavriatopoulou, 2021, Cancers.

Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid Adenoma

S. Tseleni-Balafouta, P. Makras, D. Florakis, 2019, Journal of musculoskeletal & neuronal interactions.

Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis

S. Polyzos, P. Makras, A. Anastasilakis, 2015, Expert opinion on investigational drugs.

Outbreak of meningococcal disease after an influenza B epidemic at a Hellenic Air Force recruit training center.

D. Hatzigeorgiou, P. Makras, A. Antoniadis, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hypoparathyroidism: is it that easy to treat?

M. Yavropoulou, P. Makras, A. Anastasilakis, 2018, Hormones.

Cost-effective osteoporosis treatment thresholds for people living with HIV infection in Greece

P. Makras, N. Boubouchairopoulou, I. Katsarolis, 2017, Journal of musculoskeletal & neuronal interactions.

Fracture risk among treatment-naïve postmenopausal women with osteopenia in Greece: results from the “ACROSS” study

P. Makras, A. Anastasilakis, 2020, Archives of Osteoporosis.

Development and validation of an osteoporosis treatment questionnaire (OSTREQ) evaluating physicians’ criteria in the choice of treatment

G. Lyritis, P. Makras, A. Anastasilakis, 2016, Hormones.

To screen or not to screen for osteoporosis amongst post-menopausal women with one prior osteoporotic fracture in Greece

K. Souliotis, P. Makras, C. Golna, 2022, Aging Clinical and Experimental Research.

Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.

A. Zwinderman, S. Papapoulos, P. Makras, 2009, Bone.

Growth without growth hormone (GH): a case report.

D. Papadogias, P. Makras, N. Kaklas, 2004, Hormones.

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab

K. Toulis, S. Polyzos, P. Makras, 2012, Therapeutics and clinical risk management.

Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐Year Clinical Trial

S. Polyzos, S. Papapoulos, P. Makras, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab Reduces Incidence of New Vertebral Fractures Across Severity Grades Among Postmenopausal Women with Osteoporosis.

P. Geusens, F. Jakob, B. Langdahl, 2021, Bone.

Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients

M. Yavropoulou, P. Makras, A. Anastasilakis, 2021, Bone reports.

Incidence of hip fractures in Greece during a 30-year period: 1977–2007

G. Lyritis, P. Makras, A. Galanos, 2013, Osteoporosis International.

Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study.

C. Mantzoros, S. Polyzos, B. Kalra, 2022, Metabolism: clinical and experimental.

Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case–control study

C. Mantzoros, S. Polyzos, B. Kalra, 2023, Endocrine.

Experience gained from the implementation of the fracture liaison service in Greece

E. Chronopoulos, G. Babis, T. Karachalios, 2020, Archives of Osteoporosis.

Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion

S. Polyzos, M. Yavropoulou, P. Makras, 2021, Endocrine.

Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation

S. Polyzos, M. Yavropoulou, P. Makras, 2021, Calcified Tissue International.

Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation

A. Iliopoulos, P. Makras, A. Anastasilakis, 2020, Endocrine.

Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.

S. Polyzos, M. Yavropoulou, P. Makras, 2021, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

The annual incidence of Langerhans cell histiocytosis among adults living in Greece

G. Kaltsas, M. Yavropoulou, P. Makras, 2020, Pediatric blood & cancer.

Langerhans Cell Disease (LCH)

A. Grossman, G. Kaltsas, P. Makras, 2014 .

Langerhans Cell Disease

A. Grossman, G. Kaltsas, P. Makras, 2004 .

Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?

S. Polyzos, M. Yavropoulou, P. Makras, 2018, Calcified Tissue International.

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

P. Geusens, H. Resch, A. Fahrleitner-Pammer, 2015, Osteoporosis International.

Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis.

G. Kaltsas, P. Makras, A. Anastasilakis, 2017, Metabolism: clinical and experimental.